✦ LIBER ✦

The clinical experience with antiangiogenic agents

✍ Scribed by John L. Marshall; Michael J. Hawkins

Book ID: 104873717
Publisher: Springer US
Year: 1995
Tongue: English
Weight: 756 KB
Volume: 36
Category: Article
ISSN: 0167-6806
DOI: 10.1007/bf00666045

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical experience with a new long-acti

Clinical experience with a new long-acting neuromuscular blocking agent

✍ Fawzy G. Estafanous 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 160 KB

Clinical experience with triptans

✍ Giorgio Zanchin; Filippo Dainese; Federico Mainardi; Ferdinando Maggioni 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 48 KB

Clinical experience with moxonidine

✍ B. N. C. Prichard 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 848 KB

Clinical experience with liraglutide

✍ S. C. Bain; J. McKenna 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB

Injection of antiangiogenic agents into

Injection of antiangiogenic agents into the macaque preovulatory follicle

✍ Timothy M. Hazzard; Richard M. Rohan; Theodore A. Molskness; John W. Fanton; Rob 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 324 KB

Clinical experience with the micronucleu

Clinical experience with the micronucleus assay

✍ Dr. Harinder S. Garewal; Lois Ramsey; George Kaugars; Jay Boyle 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 616 KB

Because of the logistical and practical problems that make cancer prevention trials using cancer incidence as an endpoint virtually impossible to conduct for the majority of cancer types, there is a desperate need for valid intermediate markers of cancer risk to serve as surrogate endpoints in chemo